Pharma BD Deal Intelligence
Coverage described Perrigo's stated rationale of gaining 'a diversified platform for further international expansion' and an Irish low-tax base through the…
Coverage framed Perrigo-Elan as a textbook tax-inversion play: Irish domicile and the Tysabri royalty as a dependable cash-flow anchor while Elan's…
Wells Fargo's David Maris on the combined ~$3B Irish + IRS tax exposure: 'when two tax authorities are seeking nearly $3 billion in taxes, we would suggest…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Perrigo to acquire Elan in cash-and-stock deal valued ~$8.6B; tax inversion to Ireland. Elan shareholders received $6.25 cash + 0.07636 New Perrigo shares per Elan share.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Perrigo Company plc / Elan Corporation plc (this deal) | 2013 | $8.6B | 32 |
| Perrigo Company plc / HRA Pharma | 2021 | $2.1B | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2013 deals · Other deals